BUSINESS

Kaken Grants Distribution Rights for Efinaconazole to Main Life in Hong Kong, Macau

October 3, 2018

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Kaken Pharmaceutical said on October 2 that the company and Main Life Corp. have entered into an exclusive distribution agreement for Kaken’s topical onychomycosis treatment efinaconazole in Hong Kong and Macau. Under the deal, the Hong Kong firm aims to…

To read the full story

Kaken’s Efinaconazole Launched in Hong Kong
March 4, 2020

BUSINESS

Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…